Member Info for ForFXSake

"The granting of ODD in the United States, alongside the European EMA ODD granted in April 2025, will be valuable for the potential future licensing partners we are in discussions with"

It's a shame we're not doing a treatment for agoraphobia as well...we could trial it on those partners.

Where are they?

"Its not hard to read between the li es here......."

That little typo makes the sentence spot on!

🤣

A good day for P&D merchants.

It finished exactly where it started

"FFS - What makes you think that it was a pump & dump ?"

Hmmm let me see...

Price rise on no news

Sells now outweigh buys

40 odd posts of blatant ramping

The bid has now dropped back to .17p because they can't get out quick enough

Hmmmm, this smells just like every other tedious P&D we've ever gone through.

I remember reading some guff somewhere about how re-purposed drugs were alot faster to market than new drugs 🤣

What about the GLP toxicity tests?

Also when you say non-GLP are run a few times for consistency, are they run concurrently?

Thanks Soupdragon.

Do you know if they have started them?

We already know that.

What are the required due dilligence tests and when will they be completed?

Where are the partners?

Looks like someone is cloning rampers out there!

No worries Tonto. I enjoy the exchanges.

At the end of the day, I guess we all want the 'comb' to work. It's just that the follicly-challenged among us worry whether or not all this partnering money being spent will get us a full blown hair transplant...or just a wig.

No need to report posters on my behalf TH.

I believe in free speech and don't get easily offended.

'Sticks n stones' and all that

Very rich. The ramper who resorts to throwing childish insults around when spitting the dummy out calls someone else childish.

🤣👶

Interesting!

So you think the comb (Nuformix) is actually worthless?

So why is the company value so low?

Typical P&D ramper..has to resort to insults when they feel they are not influencing..tut!

Anyway. That drivel is woolly at best, for the following reasons:

1. The RNS didn't say they wouldn't have to complete all points. It said they said it was not expected that they would....in other words, might not have. You should perhaps have read that more thoroughly.

2. Still no definite proof of large pharma. They could quite easily brush that off with "sorry the big boys pulled out...but here's an interested minnow who wants to pay peanuts" without having to reveal anything. Just hearsay for now

3. Why bother with the EMA at all if it is worthless? <** waiting for the garbage/nonsense 'ah but it is harder to get so better to have first' default ramper response **>

4. What tangible value has been added?...you seemed to miss that one

As for the £1m being enough...we'll see

Thx. Please see <** queries/comments **> :

---------------------------

TRANSCRIPT FROM DAN GOODING INTERVIEW April 1st:

Why fundraise now? <**cos we've run out of money again?**>

I think as we’ve stated, our objective is to find a licensing development partner from this moment. The orphan drug designation should help us pursue that objective towards completion <** How exactly has the EMA ODD granted a year ago now, done that? **>. TO DO SO EFFECTIVELY WE NEED TO NEGOTIATE FROM A POSITION OF FINANCIAL STRENGTH <** £1m = financial strength, really? What will be left after the due dilligence trials and salaries?**> and also progress the programme. WE NEED TO ADDRESS TECHNICAL QUESTIONS AS THEY COME UP DURING THE DUE DILIGENCE PROCESS <**Why have those questions not yet arisen if the talks have been going on so long? **>, which, as some people know, has been going on for some time <** can't argue with that **>.

So, with the raise, we’re now able to ADDRESS A SMALL NUMBER OF POINTS that have arisen from that process to date <** Why only a small number? Why not all? **> and by addressing those exact points that have arisen, we’re adding value to the programme each time we’re able to do so. <** what value is that? **>

———

They have interest from multiple partners (one being a big pharma company) <** hard proof please? **>

They are “addressing a small number of points”. <** again, why only a small number? Why not all? **>

And as per RNS not all studies need to be completed for a licensing deal.

News could come any day… <** 🥱 **>

Great response!

Calling all Trolls! Calling all Trolls!

We best retrear under the bridge. The 3 Billy Goats Gruff (tonto, zeb & littlened) are back in town

🤣

So none then?

"This looks like tremendous value under the raise"

It's definitely under the raise...price-wise, at least.